START’s Nonclinical Program is unique in that our researchers work alongside leading Phase I clinicians whose clinical experience and collaboration allows us to accelerate the movement of agents through preclinical development and into first in man studies.
The Nonclinical Program offers rapid, cost effective preclinical services focused on data quality and accessibility. Our team works closely with sponsors to develop a comprehensive drug development strategy and with hundreds of novel agents screened each year in the laboratory and clinic, we have experience with virtually every mechanistic class of oncology agent. An extensive database with efficacy and toxicity profiles for approved chemotherapeutics also allows detailed evaluation of novel agents in combination with standard therapeutic regimens.
In addition to the development of cell-based screening tools, we have established over 200 models from patient tumor tissue, which can be utilized at various stages of drug development.
Interested in learning more about the Nonclinical Programs at START? Select a preferred START location to find out more.